Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies

Benutzer: Gast

Dokumenttyp:: Zeitschriftenaufsatz
Autor(en):: Ettl, Johannes; Im, Seock-Ah; Ro, Jungsil; Masuda, Norikazu; Colleoni, Marco; Schnell, Patrick; Bananis, Eustratios; Lu, Dongrui R.; Cristofanilli, Massimo; Rugo, Hope S.; Finn, Richard S.
Titel:: Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies
Zeitschriftentitel:: Breast Cancer Research
Jahr:: 2020
Band / Volume:: 22
Heft / Issue:: 1
Volltext / DOI:: doi:10.1186/s13058-020-01263-0
Verlag / Institution:: Springer Science and Business Media LLC
E-ISSN:: 1465-542X
Publikationsdatum:: 12.03.2020
BibTeX

Vorkommen: